share_log

T2 Biosystems | 8-K: Entry into a Securities Purchase Agreement

T2 Biosystems | 8-K: Entry into a Securities Purchase Agreement

T2 Biosystems | 8-K:签订证券购买协议
美股sec公告 ·  05/20 07:05
Moomoo AI 已提取核心信息
On May 14, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported the entry into a Material Definitive Agreement with an institutional investor for a private placement. The agreement includes the sale of 1,700,000 shares of common stock, 325,317 pre-funded warrants, and series A and B warrants to purchase up to 2,025,317 shares each, generating gross proceeds of approximately $8.0 million. The pre-funded warrants and common warrants are immediately exercisable, with the series A warrants expiring five and a half years post-issuance and the series B warrants expiring 18 months post-issuance. The company also entered into a Registration Rights Agreement, obligating it to file a registration statement with the SEC by May 29, 2024, for the resale of the shares. Additionally, T2 Biosystems agreed to pay H...Show More
On May 14, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported the entry into a Material Definitive Agreement with an institutional investor for a private placement. The agreement includes the sale of 1,700,000 shares of common stock, 325,317 pre-funded warrants, and series A and B warrants to purchase up to 2,025,317 shares each, generating gross proceeds of approximately $8.0 million. The pre-funded warrants and common warrants are immediately exercisable, with the series A warrants expiring five and a half years post-issuance and the series B warrants expiring 18 months post-issuance. The company also entered into a Registration Rights Agreement, obligating it to file a registration statement with the SEC by May 29, 2024, for the resale of the shares. Additionally, T2 Biosystems agreed to pay H.C. Wainwright & Co., LLC a cash fee and management fee totaling 8% of the gross proceeds, along with $85,000 for related expenses, and issued Wainwright designees warrants to purchase up to 141,772 shares of common stock. The securities sold in this private placement have not been registered under the Securities Act and were offered pursuant to an exemption from registration requirements.
2024年5月14日,特拉华州注册成立的公司T2 Biosystems, Inc. 报告说,与一家机构投资者签订了私募的实质性最终协议。该协议包括出售1700,000股普通股、325,317份预先注资认股权证以及A系列和B系列认股权证,每份最多购买2,025,317股股票,总收益约为800万美元。预先注资的认股权证和普通认股权证可立即行使,A系列认股权证将在发行后五年半到期,B系列认股权证将在发行后18个月到期。该公司还签订了注册权协议,要求其在2024年5月29日之前向美国证券交易委员会提交一份注册声明,以转售股票。此外,T2 Biosystems同意向H.C. Wainwright & Co., LLC支付总收益的8%的现金费和管理费,以及8.5万美元的相关费用,并向Wainwright指定人员发放了购买最多141,772股普通股的认股权证。本次私募中出售的证券尚未根据《证券法》注册,是根据注册要求豁免发行的。
2024年5月14日,特拉华州注册成立的公司T2 Biosystems, Inc. 报告说,与一家机构投资者签订了私募的实质性最终协议。该协议包括出售1700,000股普通股、325,317份预先注资认股权证以及A系列和B系列认股权证,每份最多购买2,025,317股股票,总收益约为800万美元。预先注资的认股权证和普通认股权证可立即行使,A系列认股权证将在发行后五年半到期,B系列认股权证将在发行后18个月到期。该公司还签订了注册权协议,要求其在2024年5月29日之前向美国证券交易委员会提交一份注册声明,以转售股票。此外,T2 Biosystems同意向H.C. Wainwright & Co., LLC支付总收益的8%的现金费和管理费,以及8.5万美元的相关费用,并向Wainwright指定人员发放了购买最多141,772股普通股的认股权证。本次私募中出售的证券尚未根据《证券法》注册,是根据注册要求豁免发行的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息